Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases - PubMed (original) (raw)

Affiliations

PMID: 10495353

Review

Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases

F G Salituro et al. Curr Med Chem. 1999 Sep.

Abstract

p38 MAP kinase is a member of the family of kinases which mediate intracellular transduction pathways. The activation of this particular MAP kinase pathway is in response to a broad variety of extracellular stimuli. Subsequent downstream events triggered by p38 activation result in the production of IL-1 and TNF-a, suggesting that inhibition of this enzyme may provide a useful therapeutic target for intervention in various diseases mediated by these cytokines. Understanding the biological consequences of p38 activation and inhibition has been the subject of intensive research over the past several years and there is now ample evidence to suggest that inhibition of this enzyme represents a valid approach for target intervention in various cytokine-mediated diseases. Crystal structures of both apo enzyme and enzyme bound to various ligands in conjunction with site specific mutagenesis studies have provided a wealth of information regarding the interactions necessary to result in potent inhibition and selectivity from other kinases. This information has proven useful towards the analysis of previously reported compounds and will provide additional insight towards the design of new compounds and building upon existing SAR.

PubMed Disclaimer

Cited by

The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.
Duffy JP, Harrington EM, Salituro FG, Cochran JE, Green J, Gao H, Bemis GW, Evindar G, Galullo VP, Ford PJ, Germann UA, Wilson KP, Bellon SF, Chen G, Taslimi P, Jones P, Huang C, Pazhanisamy S, Wang YM, Murcko MA, Su MS. Duffy JP, et al. ACS Med Chem Lett. 2011 Jul 28;2(10):758-63. doi: 10.1021/ml2001455. eCollection 2011 Oct 13. ACS Med Chem Lett. 2011. PMID: 24900264 Free PMC article.
Inhibition of p38 mitogen-activated protein kinase augments progression of remnant kidney model by activating the ERK pathway.
Ohashi R, Nakagawa T, Watanabe S, Kanellis J, Almirez RG, Schreiner GF, Johnson RJ. Ohashi R, et al. Am J Pathol. 2004 Feb;164(2):477-85. doi: 10.1016/S0002-9440(10)63138-0. Am J Pathol. 2004. PMID: 14742254 Free PMC article.
Additive Suppression of LPS-Induced IL-10 and TNF-α by Pre-treatment of Dexamethasone and SB203580 in a Murine Alveolar Macrophage Cell Line (MH-S).
Meng A, Wang B, Zhang X, Qi N, Liu D, Wu J. Meng A, et al. Inflammation. 2015;38(3):1260-6. doi: 10.1007/s10753-014-0093-x. Inflammation. 2015. PMID: 25563207
TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha.
Piecyk M, Wax S, Beck AR, Kedersha N, Gupta M, Maritim B, Chen S, Gueydan C, Kruys V, Streuli M, Anderson P. Piecyk M, et al. EMBO J. 2000 Aug 1;19(15):4154-63. doi: 10.1093/emboj/19.15.4154. EMBO J. 2000. PMID: 10921895 Free PMC article.
Studies of chirality effect of 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine on p38alpha by molecular dynamics simulations and free energy calculations.
Chen Q, Cui W, Ji M. Chen Q, et al. J Comput Aided Mol Des. 2009 Oct;23(10):737-45. doi: 10.1007/s10822-009-9298-8. Epub 2009 Aug 12. J Comput Aided Mol Des. 2009. PMID: 19672560

Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases - PubMed (original) (raw)